Arbutus Biopharma Corp. (ABUS) Trading Up 3.5%
Shares of Arbutus Biopharma Corp. (NASDAQ:ABUS) were up 3.5% on Monday . The stock traded as high as $3.87 and last traded at $3.82, with a volume of 99,999 shares trading hands. The stock had previously closed at $3.69.
Several analysts have recently weighed in on ABUS shares. Zacks Investment Research upgraded shares of Arbutus Biopharma Corp. from a “sell” rating to a “hold” rating in a research report on Thursday, August 18th. Leerink Swann reiterated a “buy” rating on shares of Arbutus Biopharma Corp. in a research report on Wednesday, July 20th. Chardan Capital lowered shares of Arbutus Biopharma Corp. from a “neutral” rating to a “sell” rating and decreased their target price for the company from $3.25 to $2.75 in a research report on Friday, July 8th. William Blair started coverage on shares of Arbutus Biopharma Corp. in a research report on Friday, August 19th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Wedbush reiterated an “outperform” rating and set a $20.00 target price on shares of Arbutus Biopharma Corp. in a research report on Wednesday, May 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $9.39.
The company’s 50-day moving average price is $3.99 and its 200-day moving average price is $4.01. The stock’s market cap is $209.32 million.
Arbutus Biopharma Corp. (NASDAQ:ABUS) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by $0.36. Equities research analysts predict that Arbutus Biopharma Corp. will post ($3.35) EPS for the current year.
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.